This site is intended for Healthcare Professionals only

Incorrect username and/or password, please try again or click to reset.

Class 4 Medicines Defect Notification: Sandoz Limited, Co-Amoxiclav powder for oral suspension 250/62.5 mg/mL, EL(26)A/46

2026-11-05 10:00:07 (10 day(s) ago)

Summary

Sandoz Limited have informed the MHRA of errors in the dosing table in the Summary of Product Characteristics (SmPC) for Co-amoxiclav 250/62.5 mg/5 ml Powder for Oral Suspension.

Read full MHRA article

Respond to this alert